A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

The short version

This double-blind, placebo-controlled trial with 55 tuberculosis patients in Bangkok, Thailand explored whether silymarin, an extract of milk thistle (Silybum marianum) seeds long sold as a liver-support supplement, could protect the liver during standard four-drug tuberculosis treatment. Anti-tuberculosis drugs commonly injure the liver, a complication called drug-induced liver injury (governing whether treatment must be paused or adjusted), with past studies reporting it in up to nearly 28% of patients. Silymarin's traditional reputation rests on antioxidant activity, meaning it governs the body's ability to neutralize cell-damaging molecules called free radicals that these drugs generate in liver tissue. Over four weeks, participants took either a 140 mg silymarin tablet or an identical placebo three times daily alongside their standard tuberculosis medications (27 people got silymarin, 28 got placebo). Researchers tracked liver enzymes and antioxidant markers in blood tests at the study's start, two weeks, and four weeks in, and recorded any liver injury meeting a pre-set clinical definition. The trial planned to enroll 70 to 80 patients but stopped at 55 due to slow recruitment during the one-year study window. Liver injury developed in just 3.7% of the silymarin group (1 of 27 patients) compared to 32.1% of the placebo group (9 of 28), a statistically significant difference (p=.012) meaning silymarin lowered the risk by about 28 percentage points; put another way, treating about four patients with silymarin prevented one case of liver injury. Interestingly, the single peak liver-enzyme reading (ALT) at four weeks was not significantly different between groups (p=.455), so silymarin's benefit shows up in how many people develop liver injury, not necessarily in the single highest enzyme reading. An antioxidant enzyme called superoxide dismutase held up better in the silymarin group (p=.027), supporting the idea that silymarin works by boosting the body's own antioxidant defenses. Mild side effects like nausea and dizziness were equally uncommon in both groups, and no one had a serious reaction. These results suggest a low-cost silymarin tablet taken alongside standard tuberculosis treatment can meaningfully cut the chance of drug-induced liver injury, likely by protecting the liver's antioxidant capacity. The main limitation is that the study fell short of its planned enrollment (55 of 70-80 patients) at a single hospital, so despite properly randomized, double-blind design, the finding needs confirmation in larger, multi-center trials before silymarin becomes a routine addition to tuberculosis care.

Key findings

• In this randomized, double-blind, placebo-controlled trial, only 3.7% of patients taking silymarin (1 of 27) developed drug-induced liver injury from their tuberculosis medications, compared to 32.1% (9 of 28) taking placebo (p=.012).
• The number needed to treat was 3.5, meaning roughly one liver-injury case was prevented for every 3 to 4 patients given silymarin alongside their tuberculosis treatment.
• Despite this benefit, the single highest ALT liver-enzyme reading over 4 weeks was not significantly different between the silymarin and placebo groups (p=.455) -- silymarin's advantage showed up in how many people developed liver injury, not in one peak lab value.
• An antioxidant enzyme called superoxide dismutase (SOD) declined less in the silymarin group (p=.027), supporting the idea that silymarin works by helping the body neutralize the free radicals that anti-tuberculosis drugs generate in the liver.
• Mild side effects such as nausea and dizziness occurred at similarly low rates in both groups, but the trial enrolled fewer patients than planned (55 of a targeted 70-80), so larger studies are needed before silymarin is recommended as routine tuberculosis-treatment support.

Common questions